Atezolizumab + Bevacizumab Nellhcc: Il Nuovo Standard Of Care

Atezolizumab + bevacizumab nell’HCC: il nuovo standard of care

IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC

Will atezolizumab and bevacizumab be the new SOC in high-risk HCC?

Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC

Targeted Oncology

Nevena Damjanov, MD, on the outcomes of combining atezolizumab with bevacizumab in HCC patients

Atezolizumab and bevacizumab for upfront unresectable HCC

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab

Dr. McGregor on the Combination of Atezolizumab and Bevacizumab in RCC

Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC

Atezolizumab + Bevacizumab in Treatment-Naïve mRCC

Dr Bhuvan Chugh | IMbrave 150 Phase III trial of 1L Atezolizumab + Bevacizumab in patients

CRSF - Cancer Research and Statistic Foundation

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/...

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

The use of immunotherapy in HCC – efficacy and safety

COR2ED The Heart of Medical Education

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLC

Outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in HCC

Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCC

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeuti...